We identified the IgG autoantibody ANNA-2 ("anti-Ri") in 34 @entity1 in a 12-year period by immunofluorescence screening of sera from approximately 75000 @entity1 with subacute @entity16 that were suspected to be @entity8231 . Detailed clinical information was available for 28 @entity1 (10 @entity1 , 18 @entity1 ). @entity5 was diagnosed in 24 @entity1 (86%); 21 had histologically proven @entity189 (10 lung, 9 breast, 1 cervical, 1 bladder), and 3 had an intrathoracic imaging abnormality. @entity5 anteceded neurological symptoms in 4 of 28 @entity1 . @entity5 detection frequency increased with continued surveillance. @entity16 , in decreasing frequency, were @entity3308 (including opsoclonus, @entity2045 , or both), @entity76 , @entity602 , @entity1897 , @entity129 , @entity717 , @entity75 , @entity7235 , and @entity410 . Four @entity1 had @entity8822 and four had @entity3519 (two with @entity3519 ). Nine (32%) were wheelchair-bound 1 month after neurological symptom onset. Most improved neurologically after immunomodulatory or @entity5 -directed therapy. Accompanying autoantibodies, found in 73% of sera, included ANNA-1, ANNA-3, @entity21969 -IgG, P/Q-type and N-type @entity141 channel antibodies, and muscle-type @entity934 receptor antibody. Some neurological accompaniments of ANNA-2 may reflect potentially pathogenic humoral or cell-mediated responses to @entity5 antigens, for example, @entity7235 (P/Q-type @entity141 channel antibody) and @entity1897 (ANNA-1 effector T cells).

Anti-neuronal nuclear autoantibody type 2: XXXX accompaniments.

@entity1 :: ('9606', 'Species') :: ['men', 'women', 'patients'] @entity129 :: ('MESH:D003389', 'Disease') :: ['cranial neuropathy'] @entity410 :: ('MESH:D012640', 'Disease') :: ['seizures'] @entity3308 :: ('MESH:D020295', 'Disease') :: ['brainstem syndrome'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'coimmunogenic tumor', 'Cancer'] @entity2045 :: ('MESH:D009207', 'Disease') :: ['myoclonus'] @entity16 :: ('MESH:D009422', 'Disease') :: ['neurological disorders', 'Neurological disorders'] @entity602 :: ('MESH:D013118', 'Disease') :: ['myelopathy'] @entity75 :: ('MESH:D001927', 'Disease') :: ['encephalopathy'] @entity189 :: ('MESH:D002277', 'Disease') :: ['carcinoma'] @entity21969 :: ('56896', 'Gene') :: ['CRMP-5'] @entity141 :: ('CHEBI:29108', 'Chemical') :: ['Ca(2+)'] @entity1897 :: ('MESH:D010523', 'Disease') :: ['peripheral neuropathy'] @entity76 :: ('MESH:D002526', 'Disease') :: ['cerebellar syndrome'] @entity7235 :: ('MESH:D015624', 'Disease') :: ['Lambert-Eaton syndrome'] @entity8231 :: ('MESH:D010257', 'Disease') :: ['paraneoplastic'] @entity3519 :: ('MESH:D004421', 'Disease') :: ['jaw opening dystonia', 'neck dystonia'] @entity717 :: ('MESH:D009069', 'Disease') :: ['movement disorder'] @entity8822 :: ('MESH:D007826', 'Disease') :: ['laryngospasm'] @entity934 :: ('MESH:D000109', 'Chemical') :: ['acetylcholine']
@entity8231 :: (MESH:D010257,Disease) :: ['paraneoplastic']
